灵康药业: 第四届董事会第三十三次会议决议公告

Group 1 - The board of directors of Lingkang Pharmaceutical Group Co., Ltd. held its 33rd meeting on July 14, 2025, to discuss the downward adjustment of the conversion price of "Lingkang Convertible Bonds" [1][2] - The board proposed to authorize the board to handle matters related to the adjustment of the conversion price, including determining the new conversion price and effective date [1] - The meeting was attended by all 7 directors, and the resolution was deemed legal and effective [1][2] Group 2 - The proposal to adjust the conversion price requires approval at the company's first extraordinary general meeting of shareholders in 2025 [2]